merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>N/A</answer>

<other>The article mentions multiple reasons for skepticism including modest benefits, significant safety risks, and lack of correlation between amyloid removal and individual patient response, but doesn't specify a single "primary" reason.</other>

<question_number>2</question_number>
<answer>might discourage patients from participating in trials for treatments that could be better</answer>

<question_number>3</question_number>
<answer>There's no correlation in any of their studies between the removal of amyloid plaques and the clinical response in individual subjects</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>reflects the expectation that the patients can stop Kisunla after their plaques are cleared</answer>

<question_number>6</question_number>
<answer>might discourage patients from participating in trials for treatments that could be better</answer>

<question_number>7</question_number>
<answer>patients can stop the drug after it clears amyloid and Kisunla is given monthly while Leqembi is given every two weeks</answer>

<question_number>8</question_number>
<answer>amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels</answer>